Document is current
Any future updates will be listed below
-
Authors
Kühn, Michael W. M.
Pemmaraju, Naveen https://orcid.org/0000-0002-1670-6513
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (517204983, 320028127, KU-2688/2-1, KU-2688/2-2, SFB1292/2/TP12)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA016672)
- License Information
-
More Information
Article History
Received: 22 March 2025
Revised: 29 April 2025
Accepted: 30 April 2025
First Online: 15 May 2025
Competing interests
: FHH is a consultant for BMS/Celgene, AOP, Novartis, CTI, Janssen, AbbVie, GSK, Merck, CTI, Kartos, Telios and received research funding from: Novartis, BMS/Celgene and CTI. NP is a consultant / scientific advisor for Abbvie, BMS, CTI Biopharma, GSK, Immunogen, Incyte, JNJ, Karyopharm, Menarini-Stemline, Morphosys, Patylex, Protagonist, and a Board of Directors member of Dan’s House of Hope. He is supported by grants of the Sager Strong Foundation and The United States Department of Defense (DOD); MWMK receives is a consultant for Pfizer, Kura Oncology, Jazz Pharmaceuticals, Bristol-Myers Squibb/Celgene Abbvie, Servier, Johnson&Johnson, and Blueprint; is on the speaker’s bureau of Gilead, received travel support from Abbvie, Servier, Johnson&Johnson, Bristol-Myers Squibb/Celgene, and Daiichi Sankyo, and research funding from Kura-Oncology and Syndax.
